Summary of Chemomab Therapeutics FY Conference Call Company Overview - **Company**: Chemomab Therapeutics (NasdaqCM:CMMB) - **Industry**: Biotechnology, focusing on inflammatory and fibrotic diseases - **Lead Asset**: Nebokitug, a first-in-class monoclonal antibody targeting CCL24, involved in inflammation and fibrosis across multiple indications [2][3] Core Points and Arguments Clinical Development - **Primary Indications**: - Primary Sclerosing Cholangitis (PSC): A rare liver fibrotic disease with no FDA-approved drugs, approximately 70,000 patients in major markets [5][6] - Systemic Sclerosis (SSc): An inflammatory disease affecting primarily women, with a market potential exceeding $1.5 billion [20] - **Clinical Trials**: - Completed a successful Phase 2 study for PSC, showing significant anti-inflammatory and anti-fibrotic activity [3][4] - Nebokitug is now positioned as a Phase 3-ready program for PSC, with plans to start the trial with a partner [4][18] - The Phase 2 study included 76 patients, with a focus on moderate to advanced disease [7][10] Efficacy and Safety - **Phase 2 Study Results**: - Met primary and secondary endpoints, showing safety and tolerability [9][12] - Significant improvements in liver stiffness and ELF scores, particularly in patients with moderate to advanced disease [10][11][16] - 93% of eligible patients continued into an open-label extension, indicating high compliance [13] - Clinical events in treated patients were significantly lower (4.8%) compared to historical controls (26%) [17][18] Market Potential - **Revenue Projections**: Potential market for PSC could exceed $1 billion, based on conservative estimates focusing on moderate to advanced disease [6][28] - **Competitive Landscape**: Nebokitug is the only late-stage drug suggesting clear disease modification, unlike others focusing on symptom management [6][18] Future Directions - **Phase 3 Trial Design**: - Will focus on clinical events as primary endpoints, including various complications related to PSC [19] - Discussions with FDA have aligned on trial design for full approval [18] - **Expansion into Other Indications**: - Potential for nebokitug in systemic sclerosis and other fibrotic diseases, leveraging its dual anti-fibrotic and anti-inflammatory mechanism [23][24] Additional Important Information - **Financial Position**: Chemomab reported approximately $20.8 million in cash, sufficient to support activities through the end of 2026, including Phase 3 preparations [39] - **Partnership Strategy**: Seeking partners with financial commitment and expertise in commercialization to enhance trial efficiency and reduce costs [30][33] Conclusion Chemomab Therapeutics is advancing its lead asset, nebokitug, through clinical trials with promising results in treating PSC and potential applications in systemic sclerosis. The company is well-positioned for a Phase 3 trial, with significant market opportunities and a strong focus on disease modification.